P25/CDK5-mediated Tau Hyperphosphorylation in Both Ipsilateral and Contralateral Cerebra Contributes to Cognitive Deficits in Post-stroke Mice

Abstract

Objective

Post-stroke cognitive impairment (PSCI) develops in approximately one-third of stroke survivors and is associated with ingravescence. Nonetheless, the biochemical mechanisms underlying PSCI remain unclear. The study aimed to establish an ischemic mouse model by means of transient unilateral middle cerebral artery occlusions (MCAOs) and to explore the biochemical mechanisms of p25/cyclin-dependent kinase 5 (CDK5)-mediated tau hyperphosphorylation on the PSCI behavior.

Methods

Cognitive behavior was investigated, followed by the detection of tau hyperphosphorylation, mobilization, activation of kinases and/or inhibition of phosphatases in the lateral and contralateral cerebrum of mice following ischemia in MACO mice. Finally, we treated HEK293/tau cells with oxygen-glucose deprivation (OGD) and a CDK5 inhibitor (Roscovitine) or a GSK3β inhibitor (LiCl) to the roles of CDK5 and GSK3β in mediating ischemia-reperfusion-induced tau phosphorylation.

Results

Ischemia induced cognitive impairments within 2 months, as well as causing tau hyperphosphorylation and its localization to neuronal somata in both ipsilateral and contralateral cerebra. Furthermore, p25 that promotes CDK5 hyperactivation had significantly higher expression in the mice with MCAO than in the shamoperation (control) group, while the expression levels of protein phosphatase 2 (PP2A) and the phosphorylation level at Tyr307 were comparable between the two groups. In addition, the CDK5 inhibitor rescued tau from hyperphosphorylation induced by OGD.

Conclusion

These findings demonstrate that upregulation of CDK5 mediates tau hyperphosphorylation and localization in both ipsilateral and contralateral cerebra, contributing to the pathogenesis of PSCI.

Keywords

cyclin-dependent kinase 5 / p25 / post-stroke cognitive impairment / tau hyperphosphorylation

References

[1] TatemichiTK, PaikM, BagiellaE, et al.. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology, 1994, 44(10): 1885-1891

[2] LoebC, GandolfoC, CroceR, et al.. Dementia associated with lacunar infarction. Stroke, 1992, 23(9): 1225-1229

[3] AllanLM, RowanEN, FirbankMJ, et al.. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain, 2011, 134(Pt12): 3716-3727

[4] TatemichiTK, DesmondDW, MayeuxR, et al.. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology, 1992, 42(6): 1185-1193

[5] FrideY, AdamitT, MaeirA, et al.. What are the correlates of cognition and participation to return to work after first ever mild stroke?. Top Stroke Rehabil, 2015, 22(5): 317-325

[6] MijajlovicMD, PavlovicA, BraininM, et al.. Post-stroke dementia - a comprehensive review. BMC Med, 2017, 15(1): 11

[7] YangC, HawkinsKE, DoreS, et al.. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol, 2019, 316(2): C135-C153

[8] DoyleKP, SimonRP, Stenzel-PooreMP. Mechanisms of ischemic brain damage. Neuropharmacology, 2008, 55(3): 310-318

[9] WuM, ZhangM, YinX, et al.. The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases. Transl Neurodegener, 2021, 10(1): 45

[10] WangJZ, GaoX, WangZH. The physiology and pathology of microtubule-associated protein tau. Essays Biochem, 2014, 56: 111-123

[11] AlonsoAC, ZaidiT, Grundke-IqbalI, et al.. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA, 1994, 91(12): 5562-5566

[12] SenT, SahaP, JiangT, et al.. Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3beta in Alzheimer’s disease. Proc Natl Acad Sci USA, 2020, 117(8): 4418-4427

[13] HooverBR, ReedMN, SuJ, et al.. Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration. Neuron, 2010, 68(6): 1067-1081

[14] PaoPC, TsaiLH. Three decades of Cdk5. J Biomed Sci, 2021, 28(1): 79

[15] AoC, LiC, ChenJ, et al.. The role of Cdk5 in neurological disorders. Front Cell Neurosci, 2022, 16: 951202

[16] PatrickGN, ZukerbergL, NikolicM, et al.. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature, 1999, 402(6762): 615-622

[17] LeeM S, KwonY T, LiM, et al.. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature, 2000, 405(6784): 360-364

[18] DhavanR, TsaiLH. A decade of CDK5. Nat Rev Mol Cell Biol, 2001, 2(10): 749-759

[19] CheungZH, FuAKY, IpNY. Synaptic roles of Cdk5: Implications in higher cognitive functions and neurodegenerative diseases. Neuron, 2006, 50(1): 13-18

[20] AriokaM, TsukamotoM, IshiguroK, et al.. Tau protein kinase II is involved in the regulation of the normal phosphorylation state of tau protein. J Neurochem, 1993, 60(2): 461-468

[21] KimuraT, IshiguroK, HisanagaS. Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci, 2014, 7: 65

[22] ShuklaV, SkuntzS, PantHC. Deregulated Cdk5 Activity Is Involved in Inducing Alzheimer’s Disease. Arch Med Res, 2012, 43(8): 655-662

[23] TuoQZ, LeiP, JackmanKA, et al.. Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol Psychiatry, 2017, 22(11): 1520-1530

[24] LiDJ, LiYH, YuanHB, et al.. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism, 2017, 68: 31-42

[25] KubotaT, KirinoY. Age-dependent impairment of memory and neurofibrillary tangle formation and clearance in a mouse model of tauopathy. Brain Res, 2021, 1765: 147496

[26] RamsdenM, KotilinekL, ForsterC, et al.. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci, 2005, 25(46): 10637-10647

[27] PaonessaF, EvansLD, SolankiR, et al.. Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia. Cell Reports, 2019, 26(3): 582-593

[28] ShinMK, Vazquez-RosaE, KohY, et al.. Reducing acetylated tau is neuroprotective in brain injury. Cell, 2021, 184(10): 2715-2732

[29] WangJZ, Grundke-IqbalI, IqbalK. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci, 2007, 25(1): 59-68

[30] HangerDP, NobleW. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis, 2011, 2011: 352805

[31] GongCX, ShaikhS, WangJZ, et al.. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem, 1995, 65(2): 732-738

[32] SandalP, JongCJ, MerrillRA, et al.. Protein phosphatase 2A-structure, function and role in neurodevelopmental disorders. J Cell Sci, 2021, 134(13): 248187

[33] SeshadriS, WolfPA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol, 2007, 6(12): 1106-1114

[34] KalmijnS, LaunerLJ, LindemansJ, et al.. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol, 1999, 150(3): 283-289

[35] RusanenM, KivipeltoM, QuesenberryCP, et al.. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med, 2011, 171(4): 333-339

[36] TamaokaA, KalariaRN, LieberburgI, et al.. Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels. Proc Natl Acad Sci USA, 1992, 89(4): 1345-1349

[37] FujiiH, TakahashiT, MukaiT, et al.. Modifications of tau protein after cerebral ischemia and reperfusion in rats are similar to those occurring in Alzheimer’s disease - Hyperphosphorylation and cleavage of 4- and 3-repeat tau. J Cereb Blood Flow Metab, 2017, 37(7): 2441-2457

[38] MartinL, LatypovaX, WilsonCM, et al.. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev, 2013, 12(1): 289-309

[39] HangerDP, AndertonBH, NobleW. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med, 2009, 15(3): 112-119

[40] LiuYQ, KongC, GongL, et al.. The Association of Post-Stroke Cognitive Impairment and Gut Microbiota and its Corresponding Metabolites. J Alzheimers Dis, 2020, 73(4): 1455-1466

[41] Cai HY, Zhao ZY, Ni LH, et al. Structural and Functional Deficits in Patients with Poststroke Dementia: A Multimodal MRI Study. Neural Plast, 2021:3536234

[42] HilkensNA, KlijnCJM, RichardE. Blood pressure, blood pressure variability and the risk of poststroke dementia. J Hypertens, 2021, 39(9): 1859-1864

[43] PendleburyST, RothwellPM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol, 2009, 8(11): 1006-1018

[44] LevineDA, GaleckiAT, LangaKM, et al.. Risk Factors for Poststroke Cognitive Decline: The REGARDS Study (Reasons for Geographic and Racial Differences in Stroke). Stroke, 2018, 49(4): 987-994

[45] LevineDA, GaleckiAT, LangaKM, et al.. Trajectory of Cognitive Decline After Incident Stroke. JAMA, 2015, 314(1): 41-51

[46] PollockA, St GeorgeB, FentonM, et al.. Top ten research priorities relating to life after stroke. Lancet Neurol, 2012, 11(3): 209-209

[47] MartinL, LatypovaX, WilsonCM, et al.. Tau protein phosphatases in Alzheimer’s disease: The leading role of PP2A. Ageing Res Rev, 2013, 12(1): 39-49

[48] ElKN, GratuzeM, PaponMA, et al.. Insulin dysfunction and Tau pathology. Front Cell Neurosci, 2014, 8: 22

[49] PlanelE, TatebayashiY, MiyasakaT, et al.. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci, 2007, 27(50): 13635-13648

[50] ZhangY, HuangNQ, YanF, et al.. Diabetes mellitus and Alzheimer’s disease: GSK-3 beta as a potential link. Behav Brain Res, 2018, 339: 57-65

[51] LiuY, LiuF, Grundke-IqbalI, et al.. Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol, 2011, 225(1): 54-62

[52] GoncalvesRA, WijesekaraN, FraserPE, et al.. The Link Between Tau and Insulin Signaling: Implications for Alzheimer’s Disease and Other Tauopathies. Front Cell Neurosci, 2019, 13: 17

[53] YangLY, WangHY, LiuLJ, et al.. The Role of Insulin/IGF-1/PI3K/Akt/GSK3 beta Signaling in Parkinson’s Disease Dementia. Front Neurosci, 2018, 12: 73

[54] GabboujS, RyhanenS, MarttinenM, et al.. Altered Insulin Signaling in Alzheimer’s Disease Brain - Special Emphasis on PI3K-Akt Pathway. Front Neurosci, 2019, 13: 629

[55] SunKH, de PabloY, VincentF, et al.. Novel genetic tools reveal Cdk5’s major role in Golgi fragmentation in Alzheimer’s disease. Mol Biol Cell, 2008, 19(7): 3052-3069

[56] WeiFY, TomizawaK. Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus. Mini Rev Med Chem, 2007, 7(10): 1070-1074

[57] MeyerDA, Torres-AltoroMI, TanZJ, et al.. Ischemic Stroke Injury Is Mediated by Aberrant Cdk5. J Neurosci, 2014, 34(24): 8259-8267

[58] SmithPD, CrockerSJ, Jackson-LewisV, et al.. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA, 2003, 100(23): 13650-13655

[59] Gutierrez-VargasJA, MorenoH, Cardona-GomezGP. Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity. J Cereb Blood Flow Metab, 2017, 37(6): 2208-2223